Lewy Body Dementia Market Gearing Up for Outstanding Expansion During the Forecast Period (2023-32) | EIP Pharma, Cognition Therapeutics, Eisai, Eli Lilly, CuraSen Therapeutics, Athira Pharma, Aptinyx, Sun Pharma

DelveInsight's "Lewy Body Dementia Market Insights, Epidemiology, and Market Forecast 2032" report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Lewy Body Dementia Market Size and Share in the seven major markets (7MM) (i.e., the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom and Japan).

The market report covers emerging drugs, treatment practices, market share of individual Lewy Body Dementia therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current Lewy Body Dementia treatment practice/algorithm, market drivers & barriers, and unmet medical needs to curate the best of opportunities and assess the underlying potential of the market.

Lewy Body Dementia: An Overview
According to the National Institute of Health (NIH), Lewy body dementia (LBD) is a disease associated with abnormal deposits of a protein called alpha-synuclein in the brain. These deposits, called Lewy bodies, affect chemicals in the brain whose changes, in turn, can lead to problems with thinking, movement, behavior, and mood. Lewy body dementia is one of the most common causes of dementia.

Lewy body dementia affects a person's ability to think and process information - and it can negatively impact memory and alter personality. Though it shares aspects of other forms of dementia, there are distinct hallmarks of Lewy Body Dementia which include: fluctuating attention/alertness, visual hallucinations, and movement disorders. Other symptoms include REM sleep behavior disorder (RBD), depression, anxiety, insomnia, and others.

Lewy Body Dementia is now a "clinical" diagnosis, which means it represents a doctor's best professional judgment about the reason for a person's symptoms. The only way to conclusively diagnose Lewy Body Dementia is through a postmortem autopsy. Doctors perform physical and neurological examinations and various tests to distinguish Lewy Body Dementia from other illnesses. An evaluation may include medical history and examination, medical tests, brain imaging, and neuropsychological tests.

Lewy Body Dementia Market Key Facts
• The total Lewy Body Dementia market size in the 7MM was approximately USD 670 million in 2022.
• Among EU4 and the UK countries, the UK accounts for the maximum Lewy Body Dementia market size in 2022, while Spain occupies the bottom of the ladder in 2022.
• The US accounted for approximately 305 thousand cases, the highest diagnosed Lewy Body Dementia prevalent cases, followed by Japan with around 213 thousand cases, and EU4 and the UK with 202 thousand cases in 2022. These cases are expected to increase in the US, EU4, the UK, and Japan by 2032
• Among the EU4 and the UK, the UK had the highest Lewy Body Dementia diagnosed prevalent population (approximately 47 thousand cases), followed by Germany (approximately 45 thousand cases) in 2022. On the other hand, Spain (30 thousand cases) had the lowest diagnosed prevalent population in EU4 and the UK countries and the 7MM.
• Lewy Body Dementia has been identified as a male-dominant disease. In 2022, 55% of Lewy Body Dementia were males, while 45% of cases were females in the 7MM.

Get a Detailed Overview of the Evolving Lewy Body Dementia Market Trends @
https://www.delveinsight.com/report-store/lewy-body-dementia-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Lewy Body Dementia Market
The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted market size by analyzing the impact of current and emerging Lewy Body Dementia therapies in the market. It also provides a detailed assessment of the Lewy Body Dementia market drivers & barriers, unmet needs, and emerging technologies.

The report gives complete details of the market trend for each marketed Lewy Body Dementia drug and late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action (MOA), competition with other therapies, brand value, their impact on the market and view of the key opinion leaders.

Discover How the Lewy Body Dementia Market Will Grow by 2032 @
https://www.delveinsight.com/report-store/lewy-body-dementia-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Lewy Body Dementia Epidemiology
The epidemiology section covers detailed insights into the historical, and current Lewy Body Dementia patient pool and forecasted epidemiology trends for every seven major countries (7MM) from 2019 to 2032.

The Report Covers the Lewy Body Dementia Epidemiology Segmented as -
• Prevalent Population of Lewy Body Dementia (LBD)
• Gender-specific Prevalent Population of Lewy Body Dementia (LBD)
• Treatable Cases of Lewy Body Dementia (LBD)
• Diagnosed Cases of Lewy Body Dementia (LBD)

Get Key Insights Into the Evolving Lewy Body Dementia Epidemiology Trends @
https://www.delveinsight.com/report-store/lewy-body-dementia-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Lewy Body Dementia Drugs Uptake and Pipeline Development Activities
The drugs' uptake section focuses on the rate of uptake of the potential drugs recently launched in the Lewy Body Dementia market or expected to be launched during the study period. The analysis covers the market share by Lewy Body Dementia drugs, patient uptake by therapies, and sales of each drug.

The report's drugs uptake section helps in understanding the drugs with the most rapid uptake and the reasons behind the maximal use of new drugs. It allows the comparison of the drugs based on market share and size, which again will be helpful in investigating factors important in understanding the market dynamics and in making financial and regulatory decisions.

The report also covers the Lewy Body Dementia Pipeline Development Activities and provides valuable insights about different therapeutic candidates in Phase II and Phase III stages and the key companies in the market involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Explore More About Ongoing Pipeline Development Activities in the Lewy Body Dementia Market @
https://www.delveinsight.com/sample-request/lewy-body-dementia-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Lewy Body Dementia Therapeutics Assessment
There are many treatments that can help with the symptoms; all medications prescribed for Lewy Body Dementia are approved by the Food and Drug Administration to treat symptoms in other diseases, like Alzheimer's disease and Parkinson's disease. These medications can offer symptomatic benefits for cognitive, movement, sleep, mood and behavioral changes in Lewy Body Dementia.

There are not yet any medications that slow or stop the progression of Lewy Body Dementia. Cholinesterase inhibitors, such as rivastigmine (Exelon), donepezil (Aricept), and galantamine (Razadyne), are considered the standard treatment for cognitive symptoms in Lewy Body Dementia.

Leading Companies in the Lewy Body Dementia Therapeutics Market Include
• EIP Pharma Inc.
• Cognition Therapeutics
• Eisai Inc.
• Eli Lilly and Company
• CuraSen Therapeutics, Inc.
• Athira Pharma
• Aptinyx Inc.
• Sun Pharma (Georgetown University)
And Many Others

Emerging and Marketed Lewy Body Dementia Therapies Covered in the Report Include
• Neflamapimod: EIP Pharma
• CT1812: Cognition Therapeutics
• Clenbuterol: CuraSen Therapeutics, Inc
And Many Others

Learn More About the Emerging Therapies and key Companies in the Lewy Body Dementia Therapeutics Market @
https://www.delveinsight.com/sample-request/lewy-body-dementia-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Table of Content (TOC)
1. Key Insights
2. Executive Summary
3. Lewy Body Dementia Competitive Intelligence Analysis
4. Lewy Body Dementia Market Overview at a Glance
5. Lewy Body Dementia Background and Overview
6. Lewy Body Dementia Patient Journey
7. Lewy Body Dementia Epidemiology and Patient Population
8. Lewy Body Dementia Treatment Algorithm, Current Treatment, and Medical Practices
9. Lewy Body Dementia Unmet Needs
10. Key Endpoints of Lewy Body Dementia Treatment
11. Lewy Body Dementia Marketed Products
12. Lewy Body Dementia Emerging Therapies
13. Lewy Body Dementia Seven Major Market Analysis
14. Attribute Analysis
15. Lewy Body Dementia Market Outlook (7 major markets)
16. Lewy Body Dementia Access and Reimbursement Overview
17. KOL Views on the Lewy Body Dementia Market.
18. Lewy Body Dementia Market Drivers
19. Lewy Body Dementia Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
*The table of contents is not exhaustive; the final content may vary.

Download the Sample PDF to Get Detailed Insights About the Report's Offerings @
https://www.delveinsight.com/sample-request/lewy-body-dementia-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Contact Info:
Shruti Thakur
Manager (Marketing & Branding)
Email: info@delveinsight.com

428, D21 Corporate Park, Sector-21, Dwarka, New Delhi-110077, India

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

This release was published on openPR.